Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13991914 | 0.88 | NR1I2 (0.51) | EPHX2TSHRALDH1A1SMN1; SMN2NR1I2 | |
| SCHEMBL13991902 | 0.85 | EPHX2 (0.39) | EPHX2OXER1TSHRPLA2G4AALDH1A1 | |
| SCHEMBL13991893 | 0.84 | PLA2G4A (0.57) | EPHX2OXER1PLA2G4AALDH1A1LMNA | |
| SCHEMBL13286569 | 0.80 | TSHR (0.52) | EPHX2TSHRPLA2G4AALDH1A1SMN1; SMN2 | |
| SCHEMBL4927930 | 0.74 | EPHX2 (0.68) | EPHX2PLA2G4APLA2G2A | |
| SCHEMBL4777435 | 0.74 | EPHX2 (0.68) | EPHX2PLA2G4APLA2G2A | |
| SCHEMBL13993135 | 0.72 | TSHR (0.47) | EPHX2TSHRPLA2G4AALDH1A1SMN1; SMN2 | |
| SCHEMBL18339259 | 0.72 | ADORA3 (0.62) | EPHX2OXER1TSHRALDH1A1LMNA | |
| SCHEMBL12923814 | 0.72 | ADORA3 (0.62) | EPHX2OXER1TSHRALDH1A1LMNA | |
| SCHEMBL872828 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | PLA2G4A, PLA2G4B, PLA2G2A | EPHX2 140/4885OXER1 850/4885TSHR 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.